Recruiting PHASE1 INTERVENTIONAL 2-arm
NCT07348211
First in Human Study of SIM0610 in Solid Tumors (SIM0610-101)
An Open-Label, Multicenter, First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SIM0610 in Adult Subjects With Locally Advanced/Metastatic Solid Tumors
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Conditions
Advanced Solid Tumours Colorectal Cancer Head and Neck Squamous Cell Carcinoma Hepatocellular Carcinoma Non-Small Cell Lung Cancer
Interventions
SIM0610 for Injection
Updated 1 time since 2026 Last updated: Jan 21, 2026 Started: Jan 19, 2026 Primary completion: Dec 31, 2027 Completion: Jul 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07348211, this PHASE1 trial focuses on Advanced Solid Tumours and Colorectal Cancer and remains actively recruiting participants. Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd., it has been updated 1 time since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Shanghai Xianwei Medical Technology Co., Ltd.
Data source: Jiangsu Simcere Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .